Paper42579369
Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors.
Wang G and 17 others. J Clin Invest, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors. Papers, record 42579369. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42579369
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Focal Adhesion Kinase 1 | Major topic |
| Chromosomes, Human, Pair 8 | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Nerve Sheath Neoplasms | Major topic |
| Neoplasm Proteins | Major topic |
| Neurofibrosarcoma | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Cell Line, Tumor | |
| Female |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA091842 | NCI NIH HHS | United States | P30CA091842 | PubMed | NIH RePORTER |
| R01 NS134815 | NINDS NIH HHS | United States | R01NS134815 | PubMed | NIH RePORTER |
References77
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32493400 | FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors. | Breast Cancer Res | 2020 | https://conductscience.org/library/papers/32493400 | PubMed |
| 2 | 39375168 | GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. | Int J Gynecol Cancer | 2025 | https://conductscience.org/library/papers/39375168 | PubMed |
| 3 | 25062113 | Neurofibromatosis type 1 (NF1) and associated tumors. | Klin Padiatr | 2014 | https://conductscience.org/library/papers/25062113 | PubMed |
| 4 | 31285952 | Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. | Am J Cancer Res | 2019 | https://conductscience.org/library/papers/31285952 | PubMed |
| 5 | 35875109 | Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response. | Front Oncol | 2022 | https://conductscience.org/library/papers/35875109 | PubMed |
| 6 | 24861215 | Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. | Cancer Med | 2014 | https://conductscience.org/library/papers/24861215 | PubMed |
| 7 | 11526219 | Human mitochondrial topoisomerase I. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11526219 | PubMed |
| 8 | 38954182 | Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents. | Target Oncol | 2024 | https://conductscience.org/library/papers/38954182 | PubMed |
| 9 | 19479903 | Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase. | Mol Carcinog | 2009 | https://conductscience.org/library/papers/19479903 | PubMed |
| 10 | 24746704 | Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. | Cancer Cell | 2014 | https://conductscience.org/library/papers/24746704 | PubMed |
| 11 | 23221341 | MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. | J Clin Invest | 2013 | https://conductscience.org/library/papers/23221341 | PubMed |
| 12 | 33171331 | Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. | Redox Biol | 2021 | https://conductscience.org/library/papers/33171331 | PubMed |
| 13 | 32975370 | Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts. | Pediatr Blood Cancer | 2020 | https://conductscience.org/library/papers/32975370 | PubMed |
| 14 | 35446392 | The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35446392 | PubMed |
| 15 | 29117388 | Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. | J Natl Cancer Inst | 2017 | https://conductscience.org/library/papers/29117388 | PubMed |
| 16 | 34405004 | PSD3 is an oncogene that promotes proliferation, migration, invasion, and G1/S transition while inhibits apoptotic in papillary thyroid cancer. | J Cancer | 2021 | https://conductscience.org/library/papers/34405004 | PubMed |
| 17 | 27036135 | Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27036135 | PubMed |
| 18 | 29138631 | SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. | Sarcoma | 2017 | https://conductscience.org/library/papers/29138631 | PubMed |
| 19 | 38822146 | Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. | Br J Cancer | 2024 | https://conductscience.org/library/papers/38822146 | PubMed |
| 20 | 32642731 | Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives. | Neurooncol Adv | 2020 | https://conductscience.org/library/papers/32642731 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CASP3 | 836 | PubTator's text mining | https://conductscience.org/library/genes/836 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| NF1 | 4763 | PubTator's text mining | https://conductscience.org/library/genes/4763 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
| PTK2 | 5747 | PubTator's text mining | https://conductscience.org/library/genes/5747 | NCBI Gene |
| STAT3 | 6774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42579369
GET https://conductscience.org/api/papers/v1/42579369/references?page=2